Preclinical Data and Initial Clinical Experience in the Phase 1/2a Dose Escalation Trial of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases [LM]: the ReSPECT-LM Trial (SNO 2022) - Sep 28, 2022 - Abstract #CTNI-02; Pres time: Nov 19, 2022; 02:00 PM - 02:05 PM; Location: Ballroom A; "Intraventricular delivered 186RNL is promising for treatment of LM, with very early evidence of efficacy in patients. Enrollment is ongoing."
P1/2 data • Preclinical • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
|
|
Andrew J. Brenner, MD.,Ph.D; Michael Youssef, MD; Norman LaFrance; Marc Hedrick; Ande Bao, Ph.D.; William T. Phillips, MD; Toral R. Patel, MD (she/her/hers); Jeffrey S. Weinberg, MD; John Floyd, MD
|